GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
86.36
+1.36 (1.60%)
At close: Oct 28, 2025, 4:00 PM EDT
85.99
-0.37 (-0.43%)
Pre-market: Oct 29, 2025, 9:09 AM EDT
GRAIL Employees
GRAIL had 1,000 employees as of December 31, 2024. The number of employees decreased by 360 or -26.47% compared to the previous year.
Employees
1,000
Change (1Y)
-360
Growth (1Y)
-26.47%
Revenue / Employee
$134,285
Profits / Employee
-$442,952
Market Cap
3.11B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,000 | -360 | -26.47% |
| Dec 31, 2023 | 1,360 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GRAL News
- 2 days ago - GRAIL: Buy Τhe Test That Could Redefine Cancer Screening - Seeking Alpha
- 8 days ago - GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript - Seeking Alpha
- 9 days ago - GRAIL, Inc. Announces $325.0 Million Private Placement Financing - PRNewsWire
- 9 days ago - GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC) - PRNewsWire
- 11 days ago - GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings - PRNewsWire
- 11 days ago - What's Happening With GRAIL Stock? - Forbes
- 13 days ago - Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia - PRNewsWire
- 4 weeks ago - Grail: A Speculative Buy - Seeking Alpha